Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario.

IF 2.8 4区医学 Q2 ONCOLOGY

Current oncology Pub Date : 2025-05-09 DOI:10.3390/curroncol32050273

Soo Jin Seung, Anisia Wong, Raymond Milan, Nisha Chandran, Albiruni R Abdul Razak

{"title":"Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario.","authors":"Soo Jin Seung, Anisia Wong, Raymond Milan, Nisha Chandran, Albiruni R Abdul Razak","doi":"10.3390/curroncol32050273","DOIUrl":null,"url":null,"abstract":"Background: Dedifferentiated liposarcoma (DDLPS) is a rare, aggressive tumour with poor survival outcomes in advanced settings. This study assessed the incidence/prevalence, treatment patterns, survival, healthcare resource utilization (HCRU), and costs for DDLPS patients in Ontario, Canada.Methods: A retrospective cohort study was conducted among DDLPS patients between 2010 and 2022 using administrative databases. Overall survival, all-cause HCRU, and costs (2023 Canadian dollars, CAD) were compared based on advanced disease and resection status.Results: The overall incidence and cumulative prevalence of DDLPS was 0.465 and 1.995 per 100,000 people, respectively. Of all 611 DDLPS cases (64.3% male, median age [IQR]: 67 [57-76] years), 40.3% and 61.0% had advanced and unresected disease, respectively. The median overall survival (mOS) was 69 months [IQR = 15-151] for the entire cohort, but this was significantly lower for advanced and unresected disease (p < 0.0001). Among patients receiving systemic treatments (N = 117), 81.2% were prescribed doxorubicin as first-line treatment. All-cause healthcare costs (2023 CAD) amounted to CAD 34,448 per person-year (PPY), with inpatient hospitalizations being the highest cost driver at CAD 14,522 PPY and 0.8 inpatient hospitalization PPY for all years. Advanced disease had higher HCRU and costs.Conclusions: This is the first comprehensive real-world evidence study that quantifies the high mortality and cost burden associated with DDLPS in Canada.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 5","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol32050273","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Dedifferentiated liposarcoma (DDLPS) is a rare, aggressive tumour with poor survival outcomes in advanced settings. This study assessed the incidence/prevalence, treatment patterns, survival, healthcare resource utilization (HCRU), and costs for DDLPS patients in Ontario, Canada.

Methods: A retrospective cohort study was conducted among DDLPS patients between 2010 and 2022 using administrative databases. Overall survival, all-cause HCRU, and costs (2023 Canadian dollars, CAD) were compared based on advanced disease and resection status.

Results: The overall incidence and cumulative prevalence of DDLPS was 0.465 and 1.995 per 100,000 people, respectively. Of all 611 DDLPS cases (64.3% male, median age [IQR]: 67 [57-76] years), 40.3% and 61.0% had advanced and unresected disease, respectively. The median overall survival (mOS) was 69 months [IQR = 15-151] for the entire cohort, but this was significantly lower for advanced and unresected disease (p < 0.0001). Among patients receiving systemic treatments (N = 117), 81.2% were prescribed doxorubicin as first-line treatment. All-cause healthcare costs (2023 CAD) amounted to CAD 34,448 per person-year (PPY), with inpatient hospitalizations being the highest cost driver at CAD 14,522 PPY and 0.8 inpatient hospitalization PPY for all years. Advanced disease had higher HCRU and costs.

Conclusions: This is the first comprehensive real-world evidence study that quantifies the high mortality and cost burden associated with DDLPS in Canada.

查看原文本刊更多论文

加拿大去分化脂肪肉瘤（DDLPS）的流行病学、治疗模式、生存、医疗资源利用和成本：一项使用安大略省管理数据库的回顾性队列研究

背景：去分化脂肪肉瘤（DDLPS）是一种罕见的侵袭性肿瘤，晚期患者的生存率较差。本研究评估了加拿大安大略省DDLPS患者的发病率/患病率、治疗模式、生存率、医疗资源利用率（HCRU）和费用。方法：采用行政数据库对2010 - 2022年DDLPS患者进行回顾性队列研究。根据疾病晚期和切除情况比较总生存率、全因HCRU和成本（2023加元，CAD）。结果：DDLPS的总发病率为0.465 / 10万人，累积患病率为1.995 / 10万人。611例DDLPS患者（男性64.3%，中位年龄[IQR]: 67[57-76]岁）中，40.3%和61.0%为晚期和未切除的疾病。整个队列的中位总生存期（mOS）为69个月[IQR = 15-151]，但对于晚期和未切除的疾病，mOS明显较低（p < 0.0001）。在接受全身治疗的患者中（N = 117）， 81.2%的患者使用阿霉素作为一线治疗。全因医疗保健费用（2023年加币）为每人年34,448加币，住院住院费用最高，为14,522加币，全年住院住院费用为0.8加币。晚期疾病有较高的HCRU和费用。结论：这是第一个全面的真实世界证据研究，量化了加拿大与DDLPS相关的高死亡率和成本负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.